Neurocrine Biosciences (NASDAQ: NBIX) shares moved up 76.95% to $17.27. The volume of Neurocrine Biosciences shares traded was 4406% higher than normal. Neurocrine Biosciences reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.
Epizyme (NASDAQ: EPZM) shares rose 66.84% to $34.20. The volume of Epizyme shares traded was 1683% higher than normal. Epizyme reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.
ANI Pharmaceuticals (NASDAQ: ANIP) shares climbed 9.42% to $20.79. The volume of ANI Pharmaceuticals shares traded was 651% higher than normal. ANI Pharmaceuticals shares have jumped 121.45% over the past 52 weeks, while the S&P 500 index has surged 25.37% in the same period.
Cray (NASDAQ: CRAY) surged 14.40% to $31.07. The volume of Cray shares traded was 649% higher than normal. Cray affirmed its revenue outlook for 2013 and 2014.
Posted-In: volume moversNews Intraday Update Markets Movers
(c) 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Most Popular Top Stocks Under $5 For 2014 Market Wrap For January 6: Busy Day For Analysts Upgrades and Downgrades Analyst Pounds the Table on Wall Street Ethics; Adds Amazon, Apple, Philip Morris to Blacklist 3 Reasons To Invest In BP Earnings Expectations For The Week Of January 6: Alcoa And More Barron's Recap: Market Beaters Related Articles (CRAY + ANIP) Benzinga's Volume Movers Worst Performing Industries For December 31, 2013 Market Wrap For December 27: Markets Quiet Before Weekend Morning Market Movers Benzinga's Top #PreMarket Gainers Stocks To Watch For December 27, 2013 Around the Web, We're Loving... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading Techniques for the New Market Enviroment Pope Francis Rips 'Trickle-Down' Economics Come See How the Pro's Trade in this Exclusive Webinar Wynn, MGM, Other Casino Giants Vying For U.S. Turf What Should You Know About AMZN? View the discussion thread. Partner Network
No comments:
Post a Comment